A Phase 2 interventional study of Ethanol 96% Gel and Ethanol 98% Solution in Congenital Venous Malformation, sponsored by Orfagen. Completed at 2 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-01-15.
Sponsored by Orfagen · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Absolute ethanol has been used "off-label" as an unmodified formulation (solution) in Congenital Venous Malformations (CVM). Despite its effectiveness, absolute ethanol appears difficult to handle because of its high diffusion capacity outside the CVM and in the blood circulation. A less diffusible ethanol-based product (ethanol gel) has been developed in order to minimize systemic and local diffusion capacities of ethanol. Therefore, the pharmacokinetic parameters and their clinical and paraclinical outcomes between ethanol gel 96% and absolute ethanol need to be carried out.
FDA Office of Orphan Products Development (FDA OOPD) : Funding source.
Orfagen is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ethanol gel
Drug: Ethanol 96% Gel
Ethanol solution
Drug: Ethanol 98% Solution
Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax)
Blood samples were performed, just before infusion, then 5 min, 10 min, 20 min, 40 min, 60 min, 90 min, and 120 min after infusion at the first site, then every 60 min onwards until ethanol levels are found under the detection limit. Cmax was estimated directly from experimental data. If all the ethanol concentrations of a patient was below the limit of quantification of the laboratory (LOQ), Cmax was reported as LOQ/2 for this patient.
Time frame: Baseline visit (just before and during test product infusion procedure)
Systemic (Cardiopulmonary, Hematological, Metabolic) and Local Outcome of the Two Test Products.
Time frame: Study end
Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit).
Time frame: Screening and study end (Day 112)
Patient Benefit
Time frame: study end
| Milestone | L0122 Gel Group | Absolute Ethanol Group |
|---|---|---|
| Started | 17 | 14 |
| Completed | 17 | 13 |
| Not completed | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
Blood samples were performed, just before infusion, then 5 min, 10 min, 20 min, 40 min, 60 min, 90 min, and 120 min after infusion at the first site, then every 60 min onwards until ethanol levels are found under the detection limit. Cmax was estimated directly from experimental data. If all the ethanol concentrations of a patient was below the limit of quantification of the laboratory (LOQ), Cmax was reported as LOQ/2 for this patient.
| g/L | L0122 Gel Group | Absolute Ethanol Group |
|---|---|---|
| Systemic Exposure to Ethanol With the Two Test Products: Determination of the Maximum Plasma Concentration (Cmax) | 0.0604 (0.015 to 0.4) | 0.202 (0.05 to 0.940) |
Results for this outcome have not been posted.
| cm3 | L0122 Gel Group | Absolute Ethanol Group |
|---|---|---|
| Change in Volume of Congenital Venous Malformation (CVM) From Screening to Study End (Day 112 Visit). | -10.328 ± 36.667 | -126.944 ± 367.229 |
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L0122 Gel Group | — | 2/17 (11.8%) | 12/17 (70.6%) |
| Absolute Ethanol Group | — | 4/14 (28.6%) | 10/14 (71.4%) |
| Event | L0122 Gel Group | Absolute Ethanol Group |
|---|---|---|
| Blood ethanol increasedInvestigations | 0/17 | 3/14 |
| Arteriovenous malformationCongenital, familial and genetic disorders | 2/17 | 1/14 |
| Event | L0122 Gel Group | Absolute Ethanol Group |
|---|---|---|
| CoagulopathyBlood and lymphatic system disorders | 1/17 | 5/14 |
| Procedural hypotensionInjury, poisoning and procedural complications | 2/17 | 4/14 |
| HaemolysisBlood and lymphatic system disorders | 2/17 | 4/14 |
| Injection site paraesthesiaGeneral disorders | 3/17 | 0/14 |
| PainGeneral disorders | 1/17 | 1/14 |
| Complication of device insertionGeneral disorders | 0/17 | 1/14 |
| Injection site haematomaGeneral disorders | 0/17 | 1/14 |
| Injection site painGeneral disorders | 0/17 | 1/14 |
| Injection site ulcerGeneral disorders | 0/17 | 1/14 |
| Airway complication of anaesthesiaInjury, poisoning and procedural complications | 0/17 | 1/14 |
Baseline characteristics of the patients who received the study product (L0122 gel or Absolute Ethanol), whichever the amount of product was infused . 32 patients were enrolled in the study, but 31 received the study product (1 patient not treated; inclusion mistake).
| Age, Categorical(Participants) | L0122 Gel Group | Absolute Ethanol Group | Total |
|---|---|---|---|
| <=18 years | 5 | 2 | 7 |
| Between 18 and 65 years | 11 | 11 | 22 |
| >=65 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | L0122 Gel Group | Absolute Ethanol Group | Total |
|---|---|---|---|
| Female | 11 | 8 | 19 |
| Male | 6 | 6 | 12 |
| Region of Enrollment(participants) | L0122 Gel Group | Absolute Ethanol Group | Total |
|---|---|---|---|
| France | 8 | 7 | 15 |
| United States | 9 | 7 | 16 |
| Lesional volume(cm3) | L0122 Gel Group | Absolute Ethanol Group | Total |
|---|---|---|---|
| Mean | 82.712 ± 156.316 | 561.472 ± 1147.306 | 298.926 ± 801.306 |
The record gives a start of May 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 4 years 6 months after primary completion. A results delay was requested in Mar 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ethanol
Orfagen